The role of astroglia in Alzheimer's disease: pathophysiology and clinical implications

被引:249
作者
Arranz, Amaia M. [1 ,2 ]
De Strooper, Bart [1 ,2 ,3 ]
机构
[1] VIB Ctr Brain & Dis Res, Leuven, Belgium
[2] Katholieke Univ Leuven, Dept Neurosci, Leuven, Belgium
[3] UCL, Dementia Res Inst, London WC1E 6BT, England
关键词
REACTIVE ASTROCYTES; BARRIER BREAKDOWN; MICROGLIA; ACTIVATION; HEALTHY; RISK; REPLICATION; AUTOIMMUNE; PROGENITOR; PATHWAY;
D O I
10.1016/S1474-4422(18)30490-3
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Background Astrocytes, also called astroglia, maintain homoeostasis of the brain by providing trophic and metabolic support to neurons. They recycle neurotransmitters, stimulate synaptogenesis and synaptic neurotransmission, form part of the blood-brain barrier, and regulate regional blood flow. Although astrocytes have been known to display morphological alterations in Alzheimer's disease for more than a century, research has remained neurocentric. Emerging evidence suggests that these morphological changes reflect functional alterations that affect disease. Recent developments Genetic studies indicate that most of the risk of developing late onset Alzheimer's disease, the most common form of the disease, affecting patients aged 65 years and older, is associated with genes (ie, APOE, APOJ, and SORL) that are mainly expressed by glial cells (ie, astrocytes, microglia, and oligodendrocytes). This insight has moved the focus of research away from neurons and towards glial cells and neuroinflammation. Molecular studies in rodent models suggest a direct contribution of astrocytes to neuroinflammatory and neurodegenerative processes causing Alzheimer's disease; however, these models might insufficiently mimic the human disease, because rodent astrocytes differ considerably in morphology, functionality, and gene expression. In-vivo studies using stem-cell derived human astrocytes are allowing exploration of the human disease and providing insights into the neurotoxic or protective contributions of these cells to the pathogenesis of disease. The first attempts to develop astrocytic biomarkers and targeted therapies are emerging. Where next? Single-cell transcriptomics allows the fate of individual astrocytes to be followed in situ and provides the granularity needed to describe healthy and pathological cellular states at different stages of Alzheimer's disease. Given the differences between human and rodent astroglia, study of human cells in this way will be crucial. Although refined single-cell transcriptomic analyses of human post-mortem brains are important for documentation of pathology, they only provide snapshots of a dynamic reality. Thus, functional work studying human astrocytes generated from stem cells and exposed to pathological conditions in rodent brain or cell culture are needed to understand the role of these cells in the pathogenesis of Alzheimer's disease. These studies will lead to novel biomarkers and hopefully a series of new drug targets to tackle this disease.
引用
收藏
页码:406 / 414
页数:9
相关论文
共 73 条
  • [1] Relationship between cortical thickness and cerebrospinal fluid YKL-40 in predementia stages of Alzheimer's disease
    Alcolea, Daniel
    Vilaplana, Eduard
    Pegueroles, Jordi
    Montal, Victor
    Sanchez-Juan, Pascual
    Gonzalez-Suarez, Andrea
    Pozueta, Ana
    Rodriguez-Rodriguez, Eloy
    Bartres-Faz, David
    Vidal-Pineiro, Didac
    Gonzalez-Ortiz, Sofa
    Medrano, Santiago
    Carmona-Iragui, Maria
    Sanchez-Saudinos, MaBelen
    Sala, Isabel
    Anton-Aguirre, Sofia
    Sampedro, Frederic
    Morenas-Rodriguez, Estrella
    Clarimon, Jordi
    Blesa, Rafael
    Lleo, Alberto
    Fortea, Juan
    [J]. NEUROBIOLOGY OF AGING, 2015, 36 (06) : 2018 - 2023
  • [2] Blood-Brain Barrier Penetrating Biologic TNF-α Inhibitor for Alzheimer's Disease
    Chang, Rudy
    Knox, Jillian
    Chang, Jae
    Derbedrossian, Aram
    Vasilevko, Vitaly
    Cribbs, David
    Boado, Ruben J.
    Pardridge, William M.
    Sumbria, Rachita K.
    [J]. MOLECULAR PHARMACEUTICS, 2017, 14 (07) : 2340 - 2349
  • [3] Genome-wide, high-content siRNA screening identifies the Alzheimer's genetic risk factor FERMT2 as a major modulator of APP metabolism
    Chapuis, Julien
    Flaig, Amandine
    Grenier-Boley, Benjamin
    Eysert, Fanny
    Pottiez, Virginie
    Deloison, Gaspard
    Vandeputte, Alexandre
    Ayral, Anne-Marie
    Mendes, Tiago
    Desai, Shruti
    Goate, Alison M.
    Kauwe, John S. K.
    Leroux, Florence
    Herledan, Adrien
    Demiautte, Florie
    Bauer, Charlotte
    Checler, Frederic
    Petersen, Ronald C.
    Blennow, Kaj
    Zetterberg, Henrik
    Minthon, Lennart
    Van Deerlin, Vivianna M.
    Lee, Virginia Man-Yee
    Shaw, Leslie M.
    Trojanowski, John Q.
    Albert, Marilyn
    Moghekar, Abhay
    O'Brien, Richard
    Peskind, Elaine R.
    Malmanche, Nicolas
    Schellenberg, Gerard D.
    Dourlen, Pierre
    Song, Ok-Ryul
    Cruchaga, Carlos
    Amouyel, Philippe
    Deprez, Benoit
    Brodin, Priscille
    Lambert, Jean-Charles
    [J]. ACTA NEUROPATHOLOGICA, 2017, 133 (06) : 955 - 966
  • [4] Treatment for Rheumatoid Arthritis and Risk of Alzheimer's Disease: A Nested Case-Control Analysis
    Chou, Richard C.
    Kane, Michael
    Ghimire, Sanjay
    Gautam, Shiva
    Gui, Jiang
    [J]. CNS DRUGS, 2016, 30 (11) : 1111 - 1120
  • [5] The Cellular Phase of Alzheimer's Disease
    De Strooper, Bart
    Karran, Eric
    [J]. CELL, 2016, 164 (04) : 603 - 615
  • [6] Targeting Tumor Necrosis Factor Alpha for Alzheimer's Disease
    Decourt, Boris
    Lahiri, Debomoy K.
    Sabbagh, Marwan N.
    [J]. CURRENT ALZHEIMER RESEARCH, 2017, 14 (04) : 412 - 425
  • [7] Astrocyte Transforming Growth Factor Beta 1 Protects Synapses against Aβ Oligomers in Alzheimer's Disease Model
    Diniz, Luan Pereira
    Tortelli, Vanessa
    Matias, Isadora
    Morgado, Juliana
    Bergamo Araujo, Ana Paula
    Melo, Helen M.
    Seixas da Silva, Gisele S.
    Alves-Leon, Soniza V.
    de Souza, Jorge M.
    Ferreira, Sergio T.
    De Felice, Fernanda G.
    Alcantara Gomes, Flavia Carvalho
    [J]. JOURNAL OF NEUROSCIENCE, 2017, 37 (28) : 6797 - 6809
  • [8] Late onset Alzheimer's disease genetics implicates microglial pathways in disease risk
    Efthymiou, Anastasia G.
    Goate, Alison M.
    [J]. MOLECULAR NEURODEGENERATION, 2017, 12
  • [9] TNF alpha inhibitors in Alzheimer's disease: A systematic review
    Ekert, Justyna O.
    Gould, Rebecca L.
    Reynolds, Gemma
    Howard, Robert J.
    [J]. INTERNATIONAL JOURNAL OF GERIATRIC PSYCHIATRY, 2018, 33 (05) : 688 - 694